CSF2 and acute myeloid leukemia: Another biological drug belonging to the HSC-stimulating family is recombinant granulocyte monocyte colony stimulating factor (GM-CSF; Sargramostim, Leukine) which was approved by the FDA for treatment of post-chemotherapy hematopoietic recovery in older adult patients with acute myelogenous leukemia (AML) to shorten time to neutrophil recovery and acceleration of myeloid reconstitution after autologous or allogeneic bone marrow transplantation (BMT).